# Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

> **NCT06058377** · PHASE3 · RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 3680 (estimated)

## Conditions studied

- Anatomic Stage II Breast Cancer AJCC v8
- Anatomic Stage III Breast Cancer AJCC v8
- HER2-Negative Breast Carcinoma
- Hormone Receptor-Positive Breast Carcinoma

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **DRUG:** Cyclophosphamide
- **DRUG:** Doxorubicin
- **BIOLOGICAL:** Durvalumab
- **OTHER:** Genetic Testing
- **PROCEDURE:** Mammography
- **DRUG:** Paclitaxel
- **OTHER:** Quality-of-Life Assessment

## Key facts

- **NCT ID:** NCT06058377
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-27
- **Primary completion:** 2027-05-31
- **Final completion:** 2027-05-31
- **Target enrollment:** 3680 (ESTIMATED)
- **Last updated:** 2026-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06058377

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06058377, "Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06058377. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*